NCT06739252 2026-01-28
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
Phase 2 Terminated
Peking University
Mayo Clinic
Concordia Laboratories Inc.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.